Stifel analyst Thomas Stephan resumed coverage of Globus Medical (GMED) with a Hold rating and $64 price target Respondents in the firm’s spine surgeon survey expect moderating 2026 spine procedure growth and as an industry leader, Globus would likely be among the most susceptible to any market softness, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED: